Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier ...

Novartis’ Ionis-partnered drug designed to lower levels of Lp (a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular events ...

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly ...

The month of September 2025 marked a low point for relations between the U.K. government and Big Pharma.  | September 2025 ...

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million ...

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates ...

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...

The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. | ...

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a ...